Raymond James Financial’s AtriCure ATRC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$12.4M Sell
220,525
-45,530
-17% -$2.05M ﹤0.01% 1942
2026
Q2
$7.44M Buy
266,055
+49,148
+23% +$1.38M ﹤0.01% 2405
2026
Q1
$6.13M Sell
216,907
-555
-0.3% -$18.9K ﹤0.01% 2437
2025
Q4
$8.74M Sell
217,462
-19,816
-8% -$726K ﹤0.01% 2086
2025
Q3
$8.36M Sell
237,278
-15,245
-6% -$525K ﹤0.01% 2067
2025
Q2
$8.28M Buy
252,523
+5,087
+2% +$165K ﹤0.01% 2010
2025
Q1
$7.98M Buy
247,436
+125,845
+103% +$4.67M ﹤0.01% 1989
2024
Q4
$3.72M Buy
+121,591
New +$3.91M ﹤0.01% 2516

Other funds holding ATRC

Raymond James Financial's ATRC Position: Q3 2026 in Review

Raymond James Financial reduced its AtriCure (ATRC) stake by 17% in Q3 2026, selling an estimated $2.05M and leaving 220,525 shares worth $12.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1942.

Raymond James Financial first reported a position in ATRC in Q4 2024 and has held it in 8 quarters since. 286 funds tracked by Wall St. Rank hold ATRC as of Q3 2026.

  • Raymond James Financial held 220,525 shares of AtriCure worth $12.4M as of Q3 2026.
  • Raymond James Financial sold 45,530 AtriCure shares in Q3 2026, an estimated $2.05M.
  • AtriCure made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #1942 holding.
  • Raymond James Financial first reported a position in AtriCure in Q4 2024 and has held it in 8 quarters since.
  • 286 funds tracked by Wall St. Rank held AtriCure as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.